Resources Repository
-
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Priority Setting/Ethics | Health/Medicine | Oceania | Asia & Pacific | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Mental Health | Health Systems -
Resource PackPublication, Teaching Resource 2020Resource Pack: Cost-Effectiveness of SSB Excise Taxes
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior …
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior has been of increasing interest in the last decade as the evidence-base builds for the health and economic consequences of obesity, overweight, and unhealthy eating. The motivation for using fiscal instruments in nutrition policy is to make the unhealthy option less affordable and less economically attractive by increasing the price via a tax, and therefore reduce the incentive to consume…
Microsimulation | Government/Law | Health/Medicine | Oceania | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Mathematical Models | Cost-Effectiveness Analysis | Child/Nutrition | Policy/Regulation | Business/Industry | Economics/Finance | Food/Agriculture | North America | Latin America & Caribbean | Europe -
ArticlePublication 2017Modeled Health Benefits of a SSB Tax across Different Socioeconomic Groups in Australia
This analysis assessed the potential cost-effectiveness, health gains, and financial impacts of a 20% sugar-sweetened …
This analysis assessed the potential cost-effectiveness, health gains, and financial impacts of a 20% sugar-sweetened beverage (SSB) tax for Australia. Australia-specific price elasticities were used to predict decreases in SSB consumption for each socio-economic quintile. Changes in body mass index (BMI) were based on SSB consumption, BMI from the Australian Health Survey, and energy balance equations. Markov cohort models were used to estimate the health-adjusted life years (HALYs) gained, healthcare costs saved, and out-of-pocket costs…
State-Transition | Government/Law | Health/Medicine | Oceania | Chronic Disease/Risk | Mathematical Models | Policy/Regulation | Economics/Finance | Food/Agriculture -
ArticlePublication 2013Agent-Based Simulation Modelling Approach to ECEA of Health Interventions
This study develops a dynamic agent-based simulation model, the Disease Control Priorities Simulation (DCPSim) model, …
This study develops a dynamic agent-based simulation model, the Disease Control Priorities Simulation (DCPSim) model, to estimate the health and economic benefits of health interventions and policies. Authors examined two different policies that can scale up the availability of drugs for secondary prevention of acute myocardial infarction (AMI) in India: a universal public provision (UPP) that provides a drug for free at public health facilities, and a universal public finance (UPF) that provides a drug…
Priority Setting/Ethics | Dynamic Simulation | Health/Medicine | Asia & Pacific | Chronic Disease/Risk | Cost-Effectiveness Analysis | Social Determinants | Policy/Regulation -
ArticlePublication 2016Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance. All three scenarios represent a…
Priority Setting/Ethics | Microsimulation | Health/Medicine | Asia & Pacific | Chronic Disease/Risk | Cost-Effectiveness Analysis | Economics/Finance -
ArticlePublication 2016An Economic Evaluation of the PEN Program in Indonesia
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) …
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) introduced the Package of Essential Noncommunicable disease (PEN) interventions. Several countries, including Indonesia, implemented the PEN program. To assess the value of the investment in the current program, an economic evaluation of the program was conducted with collaboration between the Ministry of Health in Indonesia, the WHO, and the International Decision Support Initiative (iDSI). This study evaluated the delivery of…
Priority Setting/Ethics | Government/Law | Health/Medicine | Asia & Pacific | Chronic Disease/Risk | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Economics/Finance -
ArticlePublication 2015Publicly Financed HPV Vaccination in China: Extended Cost-Effectiveness Analysis
This extended cost-effectiveness analysis evaluates public financing of HPV vaccination in China to prevent cervical cancer. Authors …
This extended cost-effectiveness analysis evaluates public financing of HPV vaccination in China to prevent cervical cancer. Authors estimated the distribution of deaths averted by income quintile, compared vaccination paired with screening against current practice. They estimated reductions in cervical cancer incidence, net costs to the government, and patient cost savings, as well as the incremental government health care costs per death averted. When the cost per HPV vaccination is less than US$50 per vaccinated girl, vaccination was…
Priority Setting/Ethics | Microsimulation | Health/Medicine | Asia & Pacific | Chronic Disease/Risk | Cost-Effectiveness Analysis | Health Systems | Economics/Finance -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Calibration/Validation | Health/Medicine | Asia & Pacific | Sub-Saharan Africa | Chronic Disease/Risk | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Global | Middle East & North Africa | Latin America & Caribbean -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Microsimulation | Calibration/Validation | Health/Medicine | Sub-Saharan Africa | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Economics/Finance | Science/Technology